Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and ImmunityBio, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals and biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of two industry players: Bristol-Myers Squibb Company and ImmunityBio, Inc., from 2014 to 2023.

Bristol-Myers Squibb: A Steady Climb

Bristol-Myers Squibb, a giant in the pharmaceutical industry, has seen its SG&A expenses grow by approximately 36% over the past decade. Notably, the year 2020 marked a significant increase, with expenses peaking at nearly 8 billion dollars, reflecting strategic investments and expansions.

ImmunityBio: A Different Scale

In contrast, ImmunityBio, a smaller biotech firm, operates on a different scale. Despite a 30-fold increase in SG&A expenses from 2014 to 2023, their expenses remain a fraction of Bristol-Myers Squibb's, highlighting the diverse operational strategies within the sector.

This comparison underscores the varied approaches to managing operational costs in the pharmaceutical and biotech industries.